Dopamine-serotonin dysbalance in patients with dystonia

Phase 1

• Conditions: Dystonia; MedDRA version: 12.1Level: LLTClassification code 10013983Term: Dystonia

• Registration Number: EUCTR2009-018016-25-NL
• Lead Sponsor: Academic Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-02-01
• Last Update Posted: 22 May 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Age 35 years or older
Primary focal dystonia diagnosed and treated with botulinetoxin injections in the Academic Medical Center
Informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Other forms of dystonia
SSRI use in the past 6 months prior to or during the study
Use of other anti-depressants during the study, especially MAO-B inhibitors
Symptomatic therapy for dystonia other than botulinetoxin, e.g. baclofen or other muscle relaxants.
Use of medication with a known effect on dopamine or serotonin receptors or transporters or with a known interaction with Escitalopram (e.g. L-DOPA, dopamine-agonists, ritalin, NSAID’s, aspirin, tryptophan, carbamazepine, etcetera)
Pregnancy or nursing

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified